Philip Seeman
From Wikipedia, the free encyclopedia
Philip Seeman (born February 8, 1934) is a Canadian schizophrenia researcher and neuropharmacologist, known for his research on dopamine receptors.
Born in Winnipeg, Manitoba, he was raised in Montreal. He received a Bachelor of Science degree, honours Physics & Physiology (1955), a Master of Science degree, Physiology of Transport & Secretion (1956), and a Doctor of Medicine (1960) from McGill University. In 1966, he received a Ph.D. in Life Sciences from Rockefeller University.
In 1967, he became an Assistant Professor in the Department of Pharmacology at the University of Toronto. In 1970, he was appointed a Professor.
In 1974, having spent years in search for the binging site of antipsychotic medication, he discovered the dopamine D2 receptor.[1]
In 2001, he was made an Officer of the Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's". [1] In 1985, he was made a Fellow of the Royal Society of Canada.
[edit] References
- ^ Seeman P, Chau-Wong M, Tedesco J, Wong K.(1975) Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A.72(11):4376-80. PMID 1060115
[edit] External links
- Home Page of Philip Seeman's Laboratory
- Probing the Biology of Psychosis, Schizophrenia, and Antipsychotics: An Expert Interview With Dr. Philip Seeman, MD, PhD - an interview on the Medscape website.
- Schizophrenia - an essay by Philip Seeman, November 2001
